Merck & Co. (NYSE: MRK) enters October 2026 with a stock story that is stronger than a simple “good news versus bad news” checklist. The company is still producing solid revenue growth, KEYTRUDA remains exceptionally important, WINREVAIR is scaling quickly, and several pipeline programs have recently delivered encouraging clinical or regulatory updates. At the same time, Merck is investing heavily to build a post-KEYTRUDA growth platform, and those investments make current earnings unusually noisy.
For investors, the useful question is not whether MRK will rise or fall next. It is whether the evidence is improving enough to justify confidence in the trend. A high-quality analysis should help you distinguish between a durable change in business momentum and a short-term stock move driven by expectations, sentiment, or a single catalyst.
Where does MRK stand at the start of October 2026?
Because the October 6 U.S. trading session is still in progress at the time of this analysis, using an intraday quote as if it were a final daily close would be misleading. The cleaner reference point is the latest completed session. Nasdaq Dorsey Wright listed Merck at $139.54 on October 5, 2026. Investors who want to verify current or historical market data can use Nasdaq's MRK historical data page and MRK quote page.
That price should be treated as context, not a forecast. A stock can rise while business quality deteriorates if expectations were previously too low, or fall while fundamentals improve if the market had already priced in stronger results. The best way to judge the October trend is therefore to monitor whether Merck keeps clearing the operating and pipeline milestones that support its valuation.
What would a high-quality bullish outcome look like?
A constructive MRK trend would be more credible if several independent signals improve together rather than if the stock moves higher on one headline. The most important signals are revenue quality, diversification away from KEYTRUDA, evidence that newer launches can scale, and progress toward replacing revenue that will eventually face loss of exclusivity.
1. Revenue growth remains broad enough to reduce dependence on one product
Merck reported second-quarter 2026 worldwide sales of $16.607 billion, up 5% year over year, or 4% excluding foreign exchange. Pharmaceutical sales were $14.760 billion, also up 5%. The company raised and narrowed its full-year 2026 sales outlook to $66.3 billion to $67.3 billion. These figures come directly from Merck's second-quarter 2026 financial results.
The quality test is not simply whether total revenue grows. Investors should look for more products contributing meaningful incremental sales. In Q2, KEYTRUDA and KEYTRUDA QLEX generated $8.366 billion, while WINREVAIR generated $588 million and Animal Health generated $1.8 billion. If those newer and non-oncology growth engines continue to increase their share of total growth, the business becomes less dependent on one franchise.
2. WINREVAIR keeps moving from promising launch to durable growth driver
WINREVAIR sales rose 75% year over year in Q2 2026 to $588 million. In September, the U.S. Food and Drug Administration approved a label update incorporating Phase 3 HYPERION data in adults with pulmonary arterial hypertension who had been diagnosed within the prior 12 months. Merck reported that adding WINREVAIR to background therapy reduced the risk of clinical worsening events versus placebo in that study. The company summarized the approval in its September 22, 2026 WINREVAIR release.
For stock-trend quality, the next test is commercial execution. Regulatory expansion matters most when it leads to sustained prescription growth, broader geographic adoption, and a larger contribution to companywide revenue. A single quarter of rapid growth is encouraging, but durability should be judged over multiple reporting periods.
3. The oncology pipeline shows evidence that it can extend beyond KEYTRUDA alone
Merck and Moderna announced in August that the Phase 3 INTerpath-001 study of intismeran autogene plus KEYTRUDA met its recurrence-free survival and distant metastasis-free survival endpoints in completely resected stage IIB-IV melanoma. The companies said detailed data would be presented at a future medical meeting and that they planned to engage regulators. The original announcement is available from Merck.
This is relevant to MRK because the market is evaluating not just KEYTRUDA's remaining growth, but Merck's ability to create a second generation of oncology growth drivers. Positive Phase 3 outcomes improve that probability, but they do not guarantee approval, commercial success, pricing, adoption, or attractive margins. Investors should wait for detailed clinical data and regulatory progress before treating a program as established future revenue.
Why KEYTRUDA concentration still limits how far the trend can be extrapolated
Merck's own 2025 Form 10-K states that KEYTRUDA represented 49% of total company sales in 2025. The filing also says Merck expects KEYTRUDA sales to be materially negatively affected by biosimilar competition between 2028 and 2029, with competition potentially beginning in December 2028 in the United States. Those disclosures are available in the company's 2025 Form 10-K filed with the SEC.
This is the central limit of any bullish MRK thesis. Strong KEYTRUDA growth today can support near-term results while simultaneously increasing the size of the revenue base that must eventually be replaced. Investors should therefore measure diversification in dollars, not only count the number of pipeline assets. A new medicine that eventually contributes several hundred million dollars is useful; replacing a franchise of KEYTRUDA's scale requires multiple major successes.
How should investors interpret Merck's weak 2026 EPS figures?
Merck's Q2 2026 GAAP loss per share was $0.54 and non-GAAP loss per share was $0.13, but both were heavily affected by a $2.31-per-share charge related to the Terns Pharmaceuticals acquisition. Full-year 2026 non-GAAP EPS guidance of $2.66 to $2.76 also includes large one-time acquisition charges for Cidara and Terns.
For trend analysis, this means headline EPS is a low-quality standalone measure in 2026. A better result-quality framework separates three things:
- Underlying operating performance: sales growth, product-level growth and gross margin trends.
- Strategic investment: acquisition charges and R&D spending intended to expand the future portfolio.
- Economic payoff: whether acquired and internally developed assets eventually produce approved products and meaningful sales.
The correct conclusion is not to ignore acquisition costs. They are real uses of capital. The point is that 2026 EPS is unusually distorted as a measure of recurring earning power, so investors should examine both the accounting impact and the expected strategic return.
What could weaken the MRK stock trend?
A trend should be reconsidered when the underlying evidence changes. For Merck, several warning signs would matter more than a normal one-day price decline:
- KEYTRUDA growth slows faster than expected before newer products become large enough to offset it.
- WINREVAIR growth decelerates materially after the initial launch and label-expansion phase.
- Late-stage pipeline readouts disappoint or regulatory timelines slip across several important programs.
- Business-development spending fails to produce commercial assets, making acquisition charges look less like investment and more like poor capital allocation.
- Gardasil weakness or other mature-product declines deepen enough to offset newer growth drivers.
- Full-year sales guidance is reduced or management's commentary shifts from execution confidence toward demand pressure or launch delays.
One negative data point does not automatically break the thesis. The more important signal is whether multiple independent indicators deteriorate at the same time.
What should investors watch next in October?
Merck has scheduled an oncology investor event for October 26, 2026, in connection with the European Society for Medical Oncology Congress. The company disclosed the event date in its Q2 earnings materials. That event could provide additional information about oncology strategy and selected programs, but investors should distinguish between detailed clinical evidence and high-level strategic commentary.
For the rest of October, a practical checklist is:
| Signal | What would improve confidence | What would reduce confidence |
|---|---|---|
| Share price | Higher highs supported by sustained volume and fundamental news | Repeated failed rallies despite positive catalysts |
| Sales outlook | Guidance maintained or raised with broad product support | Lower guidance or narrowing driven by weaker demand |
| KEYTRUDA | Continued growth plus rising QLEX adoption | Meaningful slowdown without offsetting products |
| WINREVAIR | Strong sequential uptake and geographic expansion | Sharp deceleration after launch momentum |
| Pipeline | Detailed Phase 3 data confirm clinically meaningful benefits | Negative readouts, safety concerns or repeated delays |
| Diversification | More growth generated outside KEYTRUDA | Increasing dependence on KEYTRUDA near the patent cliff |
Bottom line: how good is the MRK trend right now?
Merck's October 2026 setup is constructive but not simple. The company is growing sales, WINREVAIR has become a meaningful new contributor, several oncology and cardiopulmonary programs have advanced, and management raised the 2026 revenue range after Q2. Those are real positives.
The limiting factor is equally clear: KEYTRUDA remains enormous, and Merck itself warns that biosimilar competition could materially affect the franchise beginning around 2028-2029. The stock therefore deserves to be judged not only on today's earnings, but on whether the company is steadily converting pipeline assets and acquisitions into enough future revenue to replace part of that concentration.
For investors evaluating MRK in October, the highest-quality outcome is not merely a higher share price. It is a higher share price accompanied by broader revenue growth, durable WINREVAIR adoption, credible late-stage oncology progress, and evidence that Merck's heavy 2026 investment is building a more diversified earnings base. If those signs weaken, the analysis should be updated rather than defended.
This article is for informational and educational purposes only and is not personalized investment advice. Stock prices can move sharply around clinical, regulatory and earnings events, and past price behavior does not guarantee future results.